Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has earned a consensus recommendation of "Buy" from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $13.20.
IMUX has been the topic of several research analyst reports. D. Boral Capital reissued a "buy" rating and issued a $17.00 price objective on shares of Immunic in a research report on Thursday, April 10th. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Immunic in a research note on Tuesday, April 15th. B. Riley restated a "buy" rating and issued a $6.00 price target on shares of Immunic in a research note on Wednesday, April 16th. StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. Finally, William Blair started coverage on shares of Immunic in a research report on Tuesday, March 25th. They issued an "outperform" rating for the company.
View Our Latest Report on Immunic
Immunic Stock Down 2.6 %
Shares of IMUX stock traded down $0.03 during trading on Tuesday, reaching $1.11. 422,903 shares of the company's stock were exchanged, compared to its average volume of 635,106. Immunic has a twelve month low of $0.83 and a twelve month high of $2.11. The firm's fifty day moving average price is $1.09 and its 200-day moving average price is $1.12. The stock has a market capitalization of $106.36 million, a PE ratio of -0.90 and a beta of 1.91.
Hedge Funds Weigh In On Immunic
Hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp grew its position in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after acquiring an additional 11,642 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock valued at $116,000 after acquiring an additional 38,553 shares in the last quarter. Virtu Financial LLC acquired a new position in Immunic during the 3rd quarter worth approximately $50,000. HB Wealth Management LLC acquired a new stake in Immunic in the 4th quarter valued at $81,000. Finally, Invesco Ltd. acquired a new position in shares of Immunic during the fourth quarter valued at about $37,000. Institutional investors own 51.82% of the company's stock.
About Immunic
(
Get Free ReportImmunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Further Reading
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
